The Food and Drug Administration (FDA) approved the drug Auvelity this week for the treatment of agitation in adults with ...

Menopause happens to every woman, and it may hold clues as to why women are at a greater risk for Alzheimer’s disease. Yale ...

AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dementia due to ...

At WIRED Health, pioneering Alzheimer's researcher John Hardy outlined the stakes—and next steps—of where treatment is headed ...

Subtle biological changes linked to Alzheimer's disease may begin as early as the late 50s—decades before memory loss or ...

The FDA expanded the indication for dextromethorphan hydrobromide and bupropion hydrochloride (Auvelity) extended-release ...

Four years after gaining FDA approval for Auvelity to treat major depressive disorder (MDD), Axsome Therapeutics has tacked ...

The FDA has approved Auvelity for treating agitation in patients with dementia due to Alzheimer’s disease, Axsome ...

Diet, gut health, cardiovascular conditions and surgical history were identified as the most prevalent drivers of Alzheimer’s ...

Researchers at the Indiana University School of Medicine have developed a new way to read the brain's "energy network ...

Hamad Medical Corporation (HMC) has announced the launch of an advanced amyloid brain PET-CT imaging service, the first of its kind in the country, delivere ...

Alzheimer’s disease and other forms of dementia affect millions of people across the globe. The organization Alzheimer’s Disease International reports that more than 55 million people worldwide were ...